TY - JOUR
T1 - Good things come in small packages
T2 - Overcoming challenges to harness extracellular vesicles for therapeutic delivery
AU - Ingato, Dominique
AU - Lee, Jong Uk
AU - Sim, Sang Jun
AU - Kwon, Young Jik
N1 - Funding Information:
DI was supported by the National Science Foundation Graduate Research Fellowship ( DGE-1321846 ). This work is also supported by the National Research Foundation of Korea (NRF) ( 2016R1A2A1A05005465 / 2010–0027955 ) sponsored by the Ministry of Science, ICT, and Future Planning (MSIP) of Korea . Y.J.K. was supported by the Brain Pool Program through the Korean Federation of Science and Technology Societies funded by MSIP.
Publisher Copyright:
© 2016 Elsevier B.V.
PY - 2016/11/10
Y1 - 2016/11/10
N2 - Extracellular vesicles (EVs) hold great promise as potential therapeutic carriers. EVs are biologically active, intrinsically transporting cargo between cells. Moreover, they can be loaded with specific cargo for distribution and/or engineered to achieve enhanced uptake. Although studies have already demonstrated therapeutic delivery using EVs, various challenges must be overcome before EV technology is ready for the clinic. Since the properties of EVs are dependent upon their cell of origin and the conditions of their formation, establishing clear characterization practices is essential to ensuring reproducibility and safety. Identifying methods for mass production of EVs is crucial for achieving high EV yields necessary for clinical trials. This review introduces current theory behind EV formation and function, describes the latest methods for characterization and mass production, and discusses future opportunities for extracellular vesicles in therapeutic delivery.
AB - Extracellular vesicles (EVs) hold great promise as potential therapeutic carriers. EVs are biologically active, intrinsically transporting cargo between cells. Moreover, they can be loaded with specific cargo for distribution and/or engineered to achieve enhanced uptake. Although studies have already demonstrated therapeutic delivery using EVs, various challenges must be overcome before EV technology is ready for the clinic. Since the properties of EVs are dependent upon their cell of origin and the conditions of their formation, establishing clear characterization practices is essential to ensuring reproducibility and safety. Identifying methods for mass production of EVs is crucial for achieving high EV yields necessary for clinical trials. This review introduces current theory behind EV formation and function, describes the latest methods for characterization and mass production, and discusses future opportunities for extracellular vesicles in therapeutic delivery.
KW - Exosomes
KW - Extracellular vesicles
KW - Microvesicles
KW - Therapeutic delivery
UR - http://www.scopus.com/inward/record.url?scp=84989172766&partnerID=8YFLogxK
U2 - 10.1016/j.jconrel.2016.09.016
DO - 10.1016/j.jconrel.2016.09.016
M3 - Review article
C2 - 27667180
AN - SCOPUS:84989172766
SN - 0168-3659
VL - 241
SP - 174
EP - 185
JO - Journal of Controlled Release
JF - Journal of Controlled Release
ER -